Dynavax Technologies Corporation (DVAX) News

Dynavax Technologies Corporation (DVAX): $13.37

0.09 (+0.68%)

POWR Rating

Component Grades








Add DVAX to Watchlist
Sign Up

Industry: Biotech




#45 of 342

in industry

Filter DVAX News Items

DVAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DVAX News Highlights

  • DVAX's 30 day story count now stands at 20.
  • Over the past 19 days, the trend for DVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about DVAX are BEAM, BEAT and DRUG.

Latest DVAX News From Around the Web

Below are the latest news stories about DYNAVAX TECHNOLOGIES CORP that investors may wish to consider to help them evaluate DVAX as an investment opportunity.

Merck (MRK) to Acquire Private Neuroscience Company for $610M

Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.

Yahoo | November 22, 2023

Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28 at 4:40 p.m. ET.

Yahoo | November 20, 2023

Bayer (BAYRY) Stops Heart Drug Study Due to Lack of Efficacy

Bayer's (BAYRY) phase III cardiovascular drug study is stopped due to low efficacy compared with Eliquis. The company suffers another setback in Roundup Litigation.

Yahoo | November 20, 2023

SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data

SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.

Yahoo | November 17, 2023

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

AstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.

Yahoo | November 17, 2023

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

Yahoo | November 16, 2023

Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates

Rocket (RCKT) gains 40% in three months on positive regulatory updates on its key candidates.

Yahoo | November 15, 2023

Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate

The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.

Yahoo | November 15, 2023

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

Yahoo | November 15, 2023

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

Yahoo | November 14, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!